

# Hydroxycarboxylic acid receptor 3 and GPR84 – two metabolite-sensing G protein-coupled receptors with opposing functions in innate immune cells

Anna Peters<sup>1</sup>, Philipp Rabe<sup>1</sup>, Aenne-Dorothea Liebing<sup>1</sup>, Petra Krumbholz<sup>1</sup>, Anders Nordström<sup>2</sup>, Elisabeth Jäger<sup>3</sup>, Robert Kraft<sup>4</sup>, Claudia Stäubert<sup>1\*</sup>

<sup>1</sup> Rudolf Schönheimer Institute of Biochemistry, Faculty of Medicine, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany

<sup>2</sup> Swedish Metabolomics Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, Linnaeus väg 6, 901 87 Umeå, Sweden

<sup>3</sup> Cedars-Sinai Medical Center, Department of Pathology, 8700 Beverly Blvd, 90048 Los Angeles (CA), USA

<sup>4</sup> Carl Ludwig Institute for Physiology, Faculty of Medicine, Leipzig University, Liebigstraße 27, 04103 Leipzig, Germany

\* To whom correspondence and requests for materials should be addressed:

Claudia Stäubert, Rudolf Schönheimer Institute of Biochemistry, Faculty of Medicine, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany, Tel.: +49-341-9722-157, Fax: +49-341-9722-159, Email: [claudia.staebert@medizin.uni-leipzig.de](mailto:claudia.staebert@medizin.uni-leipzig.de)

The data that support the findings of this study are provided with the manuscript and the supplementary material.

AP acquired, analyzed and interpreted data (DMR, cAMP, ERK, AKT, IP<sub>1</sub>, TNF $\alpha$ , NF $\kappa$ B seahorse, image-based analyses) and drafted the manuscript. ADL carried out experiments and analyzed data (cAMP, ERK, AKT, ROS). PR carried out and analyzed the RT-qPCR experiments. PK carried out experiments (cAMP, ERK, AKT). AN carried out the LC-MS experiments. RK performed the Ca<sup>2+</sup> imaging experiments, analyzed and visualized this data. EJ performed the IL-1 $\beta$  experiments. CS performed the *E. coli* growth curve and analyzed the LC-MS experiments. CS analyzed, interpreted and visualized the data, conceptually and experimentally designed the work, supervised the study and wrote the manuscript. All authors discussed the results, their implications and commented on the manuscript at all stages. All authors read and approved the final manuscript.

The authors declare that no competing interests exist.

The studies with human materials were conducted in accordance with the Declaration of Helsinki and with the recommendations of “Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig” with written informed consent from all blood donors. The protocol was approved by the aforementioned committee (313/14-ek).

**Running Title: Reciprocal modulation of innate immunity by HCA<sub>3</sub> and GPR84**

43 **Abstract**

44 G protein-coupled receptors (GPCRs) are key regulatory proteins of immune cell function  
45 inducing signaling in response to extracellular (pathogenic) stimuli. Although unrelated,  
46 hydroxycarboxylic acid receptor 3 (HCA<sub>3</sub>) and GPR84 share signaling via Gα<sub>i/o</sub> proteins and  
47 the agonist 3-hydroxydecanoic acid (3HDec). Both receptors are abundantly expressed in  
48 monocytes, macrophages and neutrophils but have opposing functions in these innate immune  
49 cells. Detailed insights into the molecular mechanisms and signaling components involved in  
50 immune cell regulation by GPR84 and HCA<sub>3</sub> are still lacking.

51 Here, we report that GPR84-mediated pro-inflammatory signaling depends on coupling to the  
52 hematopoietic cell-specific Gα<sub>15</sub> protein in human macrophages, while HCA<sub>3</sub> exclusively  
53 couples to Gα<sub>i</sub> protein. We show that activated GPR84 induces Gα<sub>15</sub>-dependent ERK activation,  
54 increases intracellular Ca<sup>2+</sup> and IP<sub>3</sub> levels as well as ROS production. In contrast, HCA<sub>3</sub>  
55 activation shifts macrophage metabolism to a less glycolytic phenotype, which is associated  
56 with anti-inflammatory responses. This is supported by an increased release of anti-  
57 inflammatory IL-10 and a decreased secretion of pro-inflammatory IL-1β. In primary human  
58 neutrophils, stimulation with HCA<sub>3</sub> agonists counteracts the GPR84-induced neutrophil  
59 activation. Our analyses reveal that 3HDec acts solely through GPR84 but not HCA<sub>3</sub> activation  
60 in macrophages.

61 In summary, this study shows that HCA<sub>3</sub> mediates hyporesponsiveness in response to  
62 metabolites derived from dietary lactic acid bacteria and uncovers that GPR84, which is already  
63 targeted in clinical trials, promotes pro-inflammatory signaling via Gα<sub>15</sub> protein in  
64 macrophages.

65

66 **Keywords**

67 hydroxycarboxylic acid receptor 3; GPR84; macrophages; neutrophils; D-phenyllactic acid;  
68 Lactic acid bacteria

69

70 **Chemical compounds studied in this article**

71 3-Hydroxydecanoic acid (PubChem CID: 26612); 3-Hydroxyoctanoic acid (PubChem CID:  
72 26613); D-(+)-3-Phenyllactic acid (PubChem CID: 643327); 1-(1-Methylethyl)-1H-  
73 benzotriazole-5-carboxylic acid (PubChem CID: 2736690); Decanoic acid (PubChem CID:  
74 2969); 6-n-Octylaminouracil (PubChem CID: 10354234)

75

76 **Abbreviations:**

77 3HDec, 3-hydroxydecanoic acid; 3HO, 3-hydroxyoctanoic acid; AC, adenylyl cyclase; C10,  
78 decanoic acid; cAMP, cyclic adenosine monophosphate; DHR123, dihydrorhodamine 123;  
79 DMR, dynamic mass redistribution; DPI, diphenyleneiodonium chloride; D-PLA,  
80 D-phenyllactic acid; ECAR, extracellular acidification rate; ETC, electron transport chain;  
81 fMLP, N-formylmethionyl-leucyl-phenylalanine; GPCR, G protein-coupled receptor; HCA,  
82 hydroxycarboxylic acid receptor; IL, interleukin; IP<sub>1</sub>, inositol monophosphate; IPBT-5CA,  
83 1-(1-Methylethyl)-1H-benzotriazole-5-carboxylic acid; LAB, lactic acid bacteria; LPS,  
84 lipopolysaccharides; MCFA, medium-chain fatty acid; NFκB, nuclear factor κ B; NET,  
85 neutrophil extracellular traps; NOX, NADPH oxidase; OCR, oxygen consumption rate; PI,  
86 propidium iodide; PLC, phospholipase C; PMA, phorbol 12-myristate 13-acetate; PMNs,  
87 polymorphonuclear neutrophil leucocytes; PTX, pertussis toxin; ROS, reactive oxygen species;  
88 TNFα, tumor necrosis factor α

89

## 90 1. Introduction

91 Hydroxycarboxylic acid receptor 3 (HCA<sub>3</sub>) and GPR84 are both rhodopsin-like G protein-  
92 coupled receptors (GPCRs). GPR84 has first been orphanized as a receptor for medium-chain  
93 fatty acids (MCFAs) (C10 – C14) and their 3-hydroxy derivatives, while HCA<sub>3</sub> was initially  
94 shown to be activated by the fatty acid oxidation intermediate 3-hydroxyoctanoic acid  
95 (3HO) [1,2]. Although GPR84 and HCA<sub>3</sub> are rather distantly related, both receptors have in  
96 common that they are abundantly expressed in innate immune cells, coupled to G $\alpha_{i/o}$  proteins,  
97 and activated by 3-hydroxydecanoic acid (3HDec) [1,3,4]. Despite these shared features, we  
98 recently showed differential signaling outcome of HCA<sub>3</sub> and GPR84 in response to 3HDec [5].  
99 Our observations from a heterologous expression system suggested that differences in  
100 endocytosis and signaling upon activation of GPR84 and HCA<sub>3</sub> may result in distinct  
101 physiological responses in cells endogenously expressing the receptors, like e.g. macrophages  
102 and neutrophils [5]. In immune cells, GPR84 has been associated with pro-inflammatory  
103 responses including induction of chemotaxis, phagocytosis and enhanced cytokine release [6–  
104 8]. For HCA<sub>3</sub>, we recently showed that fermented food-derived metabolites of lactic acid  
105 bacteria (LAB), such as D-phenyllactic acid (D-PLA), are highly potent agonists [3]. Many  
106 studies demonstrate that D-PLA increases immune tolerance through activation of anti-  
107 inflammatory processes (summarized in [3]) thus suggesting that HCA<sub>3</sub> mediates some of these  
108 effects. There are only a few studies on the physiological function of HCA<sub>3</sub> since it is only  
109 present in humans and great apes and therefore accessible animal models are lacking [3,9].  
110 Our present study is based on the assumption that the specific effects of different agonists acting  
111 on HCA<sub>3</sub> and GPR84 are the basis for recognizing their function in immune cells. Since the  
112 bacterial origin of 3HDec, which activates both receptors, has only been shown indirectly in  
113 clinical samples [10], we analyzed *in vitro* *E. coli* culture medium for their relative 3HDec  
114 concentration in different growth phases. Further, we aimed to elucidate the molecular  
115 mechanisms relevant for the interplay of HCA<sub>3</sub> and GPR84 in innate immune cells.  
116 Macrophages polarized from the human monocytic THP-1 cell line and freshly isolated  
117 polymorphonuclear neutrophil leucocytes (PMNs) were analyzed regarding their HCA<sub>3</sub> and  
118 GPR84-mediated cellular functions. Both, macrophages and PMNs provide the first line of  
119 defense against invading microorganisms [11,12] and their cellular functions include  
120 phagocytosis, chemotaxis, the production of reactive oxygen species (ROS) as well as the  
121 release of anti-microbial peptides, lytic enzymes and different cytokines [13–15].  
122 We found that although both, HCA<sub>3</sub> and GPR84, are described as solely coupled to G $\alpha_{i/o}$ ,  
123 GPR84 is also coupled to the G $\alpha_{15}$  protein in macrophages. Activation of GPR84 by C10 and  
124 3HDec caused a G $\alpha_{15}$  protein-mediated increase in intracellular Ca<sup>2+</sup> levels, IP<sub>1</sub> levels and ERK  
125 activation, associated with an enhanced ROS production. In contrast to our own previously  
126 obtained data in heterologous expression systems [5], here no HCA<sub>3</sub>-mediated effects upon  
127 activation by 3HDec were observed. However, stimulation of HCA<sub>3</sub> by D-PLA, 3HO or the  
128 surrogate agonist IPBT-5CA reduced interleukin-1 $\beta$  (IL-1 $\beta$ ) secretion, but increased anti-  
129 inflammatory interleukin-10 secretion in macrophages. This is reflected metabolically by a less  
130 glycolytic phenotype in presence of HCA<sub>3</sub> agonists, which is a characteristic feature of anti-  
131 inflammatory responses of macrophages [16]. Similarly, we show that GPR84 agonists activate  
132 PMNs, while this is counteracted by HCA<sub>3</sub> signaling.

133

## 134 2. Materials and Methods

### 135 2.1 Chemicals and Media

136 All compounds, inhibitors and cytokines were purchased from Sigma-Aldrich, Cayman  
137 Chemical or Santa Cruz Biotechnology if not stated otherwise. All protocols were followed  
138 according to the respective manufacturers' instructions, if not explicitly specified differently.

139 All media, antibiotics and fetal bovine serum (FBS) were obtained from Thermo Fisher  
140 Scientific if not stated otherwise. HBSS buffer was supplemented with 20 mM HEPES and the  
141 pH was adjusted to 7.4 if not stated otherwise.

142

## 143 **2.2 Isolation of PMNs (polymorphonuclear neutrophil leucocytes)**

144 Blood was taken from healthy blood donors and experiments were conducted in accordance  
145 with the Declaration of Helsinki according to a protocol approved by the Ethics Review Board  
146 of the Medical Faculty, Leipzig University (313/14-ek and 430/16-ek), with written informed  
147 consent from all blood donors.

148 PMNs were freshly isolated from human peripheral blood employing the alternate protocol  
149 described by Kuhns et al. [17]. In brief, following Ficoll-Paque-based density gradient  
150 centrifugation, the PMN- and erythrocyte-rich pellet was mixed with 3 % dextran to separate  
151 them by allowing the erythrocytes to sediment at 1 x g for 20 min. Subsequently, the PMN-rich  
152 supernatant was centrifuged at 300 x g for 10 min, remaining erythrocytes in the PMN-  
153 containing pellet were lysed (2 cycles), finally cells were washed, resuspended in HBSS (-)  
154 (without Calcium/Magnesium) and stored at RT at a density of 1 - 2.5 x 10<sup>7</sup> cells/ml until  
155 seeded for respective assay. If not otherwise stated, for all analyses involving PMNs, 5 x 10<sup>4</sup>  
156 freshly isolated cells per well were seeded in a 96-well plate in HBSS.

157

## 158 **2.3 Cell culture**

159 THP-1 cells obtained from the DSMZ-German Collection of Microorganisms and Cell  
160 Cultures, THP-1-Lucia NFκB cells, stably expressing an NFκB-inducible Lucia reporter  
161 construct, purchased from InvivoGen and the human embryonic kidney cell line HEK293-T  
162 (ATCC CRL-3216) were maintained at 37 °C in a humidified 5 % CO<sub>2</sub> incubator. Both THP-1  
163 cell lines were grown in RPMI-1640 supplemented with 10 % heat inactivated (HI, 30 min at  
164 56 °C) fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin and split  
165 every 3-4 days (THP-1 cells: 4 x 10<sup>6</sup> cells/T75-flask in 20 ml, THP-1-LuciaNFκB cells:  
166 10 x 10<sup>6</sup> cells/T75-flask in 20 ml). Medium of THP-1-Lucia NFκB was additionally  
167 supplemented with 100 µg/ml Normocin (InvivoGen) and every other passage with 100 µg/ml  
168 Zeocin. Activation of the NFκB-inducible Lucia reporter results in secretion of luciferase into  
169 the cell culture supernatant. HEK293-T cells were cultured in Dulbecco's Modified Eagle  
170 medium (DMEM) containing 10 % FBS, 100 U/ml penicillin and 100 µg/ml streptomycin.

### 171 2.3.1 Differentiation and polarization of THP-1 cells

172 THP-1 cells were split into 96-well (analyses-dependent: Greiner or Seahorse XF cell culture  
173 plates) or 24-well plates (depending on the assay) at a density of 5 x 10<sup>4</sup> or 5 x 10<sup>5</sup> cells/well  
174 and differentiated with 50 ng/ml PMA for 48 h. To subsequently polarize THP-1 cells into M0-,  
175 M1- or M2-like macrophages, cells were incubated for another 48 h in RPMI-1640  
176 supplemented with 10 % HI-FBS (M0), RPMI-1640 + 10 % HI-FBS + 20 ng/ml LPS +  
177 20 ng/ml IFNγ (M1), or RPMI-1640 + 10 % HI-FBS + 25 ng/ml IL-4 + 25 ng/ml IL-13 (M2)  
178 as previously described [18]. THP-1-Lucia NFκB cells were differentiated and polarized using  
179 the same protocol, only the cell density was adapted to 1 x 10<sup>5</sup> cells/well in 96-well plates.

180 THP-1 cells were polarized to M1-like macrophages for RT-qPCR analyses, cAMP inhibition  
181 and IP<sub>1</sub> accumulation assays, ERK and AKT activation analyses, detection of human IL-1β and  
182 TNFα, prior Ca<sup>2+</sup> imaging and analyses of ROS production as well as for the Seahorse XF Cell  
183 Mito Stress Test.

### 184 2.3.2 siRNA transfection of THP-1 cells

185 Differentiated THP-1 cells were transfected with siRNA (OriGene) specifically targeting  
186 HCA<sub>3</sub>, GPR84 or GNA15 (supplementary Table S1), respectively, using Viromer Green  
187 (Lipocalyx). Prior to the transfection, the medium was changed to M1-polarizing medium. 10

188  $\mu\text{l}$  or 100  $\mu\text{l}$  of siRNA-Viromer mix were added to each well in 96- or 24-well plates,  
189 respectively. Assays were performed 24 h - 48 h post transfection.

190

## 191 **2.4 RNA preparation, reverse transcription and quantitative real-time PCR**

192 For preparation of RNA the ReliaPrep RNA Cell Miniprep System (Promega) was used. RNA  
193 of freshly isolated PMNs ( $1.7 \times 10^6 \approx$  PMNs in 1 ml blood) was extracted using the SV Total  
194 RNA Isolation System (Promega). PMNs were centrifuged and immediately lysed in lysis  
195 buffer supplied with the Kit. THP-1 cells were seeded in 24-well plates ( $5 \times 10^5$  cells/well),  
196 differentiated and polarized to M0-, M1- or M2-like macrophages and then harvested. Yielded  
197 RNA concentrations were measured using a Nano Drop spectrophotometer and RNA was stored  
198 at  $-80^\circ\text{C}$ .

199 Prior to reverse transcription, 500 ng RNA were treated with 1  $\mu\text{l}$  DnaseI (NEB) in a total  
200 reaction volume of 10  $\mu\text{l}$  for 30 min at  $37^\circ\text{C}$ . Reactions were stopped by addition of 1  $\mu\text{l}$  50 mM  
201 EDTA and heat inactivation for 10 min at  $75^\circ\text{C}$ . Directly thereafter, RNA was reverse  
202 transcribed using iScript cDNA Synthesis Kit (Bio-Rad). Transcribed cDNA was diluted with  
203 RNase-free  $\text{H}_2\text{O}$  to a final volume of 70  $\mu\text{l}$ . The qPCR set-up was as follows: each reaction  
204 (12  $\mu\text{l}$ ) contained 1  $\mu\text{l}$  of cDNA, 1  $\mu\text{l}$  of premixed sense and anti-sense primer (400 nM each),  
205 5  $\mu\text{l}$  of RNase-free  $\text{H}_2\text{O}$  and 5  $\mu\text{l}$  of Luna Universal qPCR Master Mix (NEB).

206 The following thermal cycling protocol was used: polymerase activation at  $95^\circ\text{C}$  for 2 min,  
207 followed by 40 cycles of 15 s of denaturation at  $95^\circ\text{C}$  and 30 s of monitored  
208 annealing/extension at  $60^\circ\text{C}$ . Subsequently, melt curves were recorded ( $55^\circ\text{C} - 95^\circ\text{C}$ ,  $0.5^\circ\text{C}$   
209 increment, 5 s/step). Real-time PCR and data collection ( $C_q$  determination mode: regression)  
210 were performed on Bio-Rad CFX Connect Real-Time PCR Detection System. Indicated n  
211 reflect biological replicates, that were reverse-transcribed and qPCR was run in duplicates.  
212 Primers were designed using Primer-Blast (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/>)  
213 and ordered from Microsynth Seqlab. Melt curves after the qPCR run showed one single sharp  
214 peak for each primer pair listed in supplementary Table S1.

215

## 216 **2.5 Functional assays**

### 217 2.5.1 Dynamic mass redistribution (DMR) assay

218 To measure label-free receptor activation, DMR Measurements (Epic technology, Corning Life  
219 Sciences) were performed with PMNs. Freshly isolated PMNs were resuspended in HBSS with  
220 or without 3  $\mu\text{g}/\text{ml}$  PTX and incubated for 60 min at RT prior to seeding them in an uncoated  
221 Epic 384-well microplate at a density of  $8 \times 10^4$  cells per well. Seeding was followed by 45 min  
222 of equilibration, subsequent stimulation with various agonists was performed and DMR was  
223 recorded for 60 min. In DMR measurements, polarized light is passed through the bottom of  
224 the biosensor microplate, and a shift in wavelength of reflected light indicates intracellular mass  
225 redistribution triggered by receptor activation.

### 226 2.5.2 ALPHAScreen cAMP assay

227 Cyclic AMP content of cell extracts was determined using the ALPHAScreen cAMP Detection  
228 Kit (Perkin Elmer). Stimulation with various agonists at different concentrations was performed  
229 in HBSS with 1 mM 3-isobutyl-1-methylxanthine (IBMX) and 2  $\mu\text{M}$  forskolin for 15 min at  
230  $37^\circ\text{C}$ . Reactions were stopped by aspiration of stimulation buffer and cells were lysed in  
231 100  $\mu\text{l}/\text{well}$  of lysis buffer containing 1 mM IBMX. From each well 5  $\mu\text{l}$  of lysate were  
232 transferred to a 384-well plate and proceeded as previously described [5].

### 233 2.5.3 Alpha SureFire Multiplex pERK 1/2 & total ERK Assay and pAKT1/2/3 & total AKT1 234 Assay

235 The pERK/total ERK and pAKT/total AKT ratios of cell extracts were determined using the  
236 Alpha SureFire Ultra Multiplex p-ERK 1/2 (Thr202/Tyr204) & Total ERK assay and the  
237 p-AKT1/2/3(Ser473) & Total AKT1 assay technology, respectively (Perkin Elmer).

238 For both assays, THP-1 cells and freshly isolated PMNs were seeded in 96-well plates.  
239 Stimulation with agonists was performed in HBSS buffer with 20 mM HEPES for 10 min at  
240 37 °C. For assays with both cell types, reactions were stopped by aspiration of stimulation  
241 buffer and lysis of cells in 50 µl/well of supplied lysis buffer supplemented with 250 µM  
242 protease inhibitor cocktail Pefabloc (AEBSF). From each well 10 µl of lysate were transferred  
243 to a 384-well plate and acceptor beads and donor beads were added.

#### 244 2.5.4 HTRF IP<sub>1</sub> assay

245 IP<sub>1</sub> content of cell extracts was determined by using the HTRF Technology (Cisbio).  
246 Stimulation with various agonists at different concentrations was performed in 35 µl/well  
247 supplied stimulation buffer for 60 min at 37 °C. Reactions were stopped by placing cells on ice  
248 and addition of 30 µl/well of supplied lysis buffer. From each well 7 µl of lysate were  
249 transferred to a 384-well low volume plate. Acceptor and donor antibodies were added.

#### 250 2.5.5 Ca<sup>2+</sup> imaging

251 THP-1 cells, polarized to M1-like macrophages and transfected with siRNA when applicable,  
252 were seeded in 24-well plates on glass cover slips. For imaging experiments, cells were loaded  
253 with 5 µM fura-2AM (Molecular Probes) for 60 min in a standard solution containing 140 mM  
254 NaCl, 10 mM HEPES, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, and 10 mM glucose. Fura 2-  
255 based measurements were performed in single cells using a monochromator-based imaging  
256 system and the software TILLvision 4.0 (T.I.L.L. Photonics). Emitted fluorescences (excited  
257 at 340 nm and 380 nm) were acquired with a CCD camera (PCO Imaging) at intervals of 2 s  
258 and corrected for background fluorescence. Stock solutions of GPR84 and HCA<sub>3</sub> agonists as  
259 well as fMLP and ATP were dissolved in standard solution and applied to the cells by bath  
260 perfusion.

#### 261 2.5.6 Detection of Human IL-1β, IL-10, TNFα

262 Human IL-1β, IL-10 and TNFα concentrations in cell culture supernatants were determined  
263 employing the Human IL-1β ELISA Set II (BD Bioscience), the Human IL-10 ELISA Set (BD  
264 Bioscience) and the Human TNFα HTRF-Kit (Cisbio), respectively, according to the  
265 manufacturer's protocol. Stimulation with agonists was performed in RPMI-1640 + 10 % FBS  
266 37 °C (8 h, 500 µl/well: IL-1β, IL-10; 5 h, 60 µl/well: TNFα). Reactions were stopped by  
267 aspiration of supernatants, which were subsequently frozen and stored (IL-1β, IL-10: -20 °C,  
268 TNFα: -80 °C) for later analysis.

#### 269 2.5.7 NFκB luciferase assay

270 THP-1-Lucia NFκB cells were seeded in 96-well plates and differentiated with PMA for 48 h.  
271 Stimulation with agonists was performed in M1-polarization medium (using RPMI-1640  
272 without phenol red) for 48 h at 37 °C and 5 % CO<sub>2</sub>. To measure luciferase activity  
273 corresponding to NFκB activation, 20 µl/well of cell culture supernatant were transferred to a  
274 black 96-well plate, 50 µl/well of QUANTI-Luc assay solution (InvivoGen,) were added in the  
275 dark and luminescence was immediately measured using the EnVision multimode plate reader  
276 (Perkin Elmer).

#### 277 2.5.8 Seahorse XF Cell Mito Stress Test

278 THP-1 cells were seeded in 96-well Seahorse XF cell culture plates and polarized to M1-like  
279 macrophages. Medium was changed to Phenol Red-free non-buffered Seahorse XF RPMI  
280 Medium containing 10 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate. The  
281 oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured  
282 using the mitochondrial stress test (Agilent) according to the manufacturer's protocol under  
283 basal conditions and in response to 1 µM oligomycin, 0.5 µM fluoro-carbonyl cyanide  
284 phenylhydrazone (FCCP) and 0.5 µM rotenone / 0.5 µM antimycin A with the XF96  
285 Extracellular Flux Analyzer (Seahorse Bioscience). ECAR, a proxy for lactate production, and  
286 OCR were recorded to assess the glycolytic activity and mitochondrial respiratory activity,  
287 respectively. Upon completion of the Seahorse assay, cells were stained with Hoechst 33342

288 (1:5000, Sigma-Aldrich) for 15 min at 37 °C to determine the total cell numbers per well. Plates  
289 were imaged and automatically analyzed using the Celigo Imaging Cytometer (Nexcelom  
290 Bioscience). Cell count was used for normalization of Seahorse Mito Stress Test data. The  
291 components of the ETC are localized in mitochondria and composed of complex I (inhibited by  
292 rotenone), complex II, complex III (inhibited by antimycin A), and complex IV, which reduces  
293 oxygen (OCR) (Figure 4C). The proton gradient generated by electron transfer along the ETC  
294 is used by the ATP synthase (inhibited by oligomycin) to generate adenosine triphosphate  
295 (ATP). FCCP uncouples the ETC from ATP production by depletion of the proton gradient.  
296 The ECAR reflects the cytosolic proton concentration, which is a measure of the rate of  
297 glycolysis. The parameters were calculated as follows: **non-mitochondrial oxygen**  
298 **consumption** (= minimum rate OCR measurement after rotenone / antimycin A injection),  
299 **basal respiration** (baseline OCR - non-mitochondrial respiration), **ATP production** (basal  
300 respiration - OCR after oligomycin injection), **maximal respiration** (maximum OCR after  
301 FCCP injection - non-mitochondrial respiration), **spare respiratory capacity as %** (maximal  
302 respiration / basal respiration x 100).

### 303 2.5.9 Determination of HCA<sub>3</sub> and GPR84 knockdown efficiency using ELISA

304 HEK-293T cells were seeded in T-25 cell culture flasks (1.6 x 10<sup>6</sup> cells/flask) and co-transfected  
305 with receptor-specific siRNA or siNC and plasmid encoding N-terminally HA-tagged GPR84  
306 or N-terminally HA-tagged HCA<sub>3</sub>, respectively. Plasmids described in [5]. Lipofectamine 2000  
307 (Life Technologies, Darmstadt, Germany) with 2 µg plasmid and 200 pmol siRNA was used  
308 for transient transfection. 24 h after transfection, cells were harvested and plated in 48-well  
309 plates (1 x 10<sup>5</sup> cells/well; cell surface expression). Cell surface expression was measured using  
310 an direct cellular ELISA as described in [5].  
311

## 312 **2.6 Image-based analyses**

### 313 2.6.1 ROS formation

314 To measure NADPH oxidase-dependent ROS formation, THP-1 cells were seeded in 96-well  
315 plates, incubated with 5 µM dihydrorhodamine 123 (DHR123), and stimulated with receptor  
316 agonists for 24 h at 37 °C in the presence or absence of 4 µM NADPH oxidase inhibitor  
317 diphenyleneiodonium chloride (DPI). The assay was performed in HBSS containing 10 %  
318 THP-1 cell culture medium. Following incubation, buffer containing agonists and DHR123 +/-  
319 DPI was removed from plates and replaced by fresh HBSS. Plates were imaged immediately  
320 and automatically analyzed using the Celigo Imaging Cytometer (Nexcelom Bioscience).

### 321 2.6.2 PMN activation/NET formation assay

322 PMNs were seeded in 96-well plates, receptor agonists were added, followed by incubation at  
323 37 °C for 20 h. Finally, PMNs were stained with propidium iodide (PI, 1:2500, 1 mg/ml stock,  
324 Thermo Fisher Scientific) and Hoechst 33342 (1:5000, Sigma-Aldrich) for 15 min at 37 °C to  
325 measure activated and total cell numbers, respectively. Plates were imaged and automatically  
326 analyzed using the Celigo Imaging Cytometer (Nexcelom Bioscience).

### 327 2.6.3 Phagocytosis

328 PMNs were seeded in black Greiner 96-well plates with clear bottom, receptor agonists were  
329 added, followed by incubation at 37 °C for 30 min. The *E. coli* pHrodo Red-conjugated  
330 BioParticles (Thermo Fisher Scientific) were added to the plate at a final concentration of 0.1  
331 mg/ml, followed by incubation at 37 °C for 60 min. Subsequently, the *E. coli* particles were  
332 removed, cells were washed 3 x with PBS and fixed with 4 % formalin for 15 min at room  
333 temperature (RT). Next, the cells were washed once with PBS, permeabilized using 0,5 %  
334 Triton X-100 in PBS at RT for 10 min, washed twice with PBS and finally stained with Alexa  
335 Fluor 488 Phalloidin (1:40, Thermo Fisher Scientific) and Hoechst 33342 (1:5000) for 10 min  
336 at RT. Plates were imaged and analyzed using the Celigo Imaging Cytometer (Nexcelom

337 Bioscience). Confocal images were acquired using a 40 x objective employing the Confocal  
338 Quantitative Image Cytometer CQ1 (Yokogawa/Cenibra).

339

## 340 **2.7 Liquid Chromatography Mass Spectrometry (LC-MS) measurement**

341 *E. coli* K-12 MG1655 were cultured for 24 hours in M9 mineral medium containing M9 salt  
342 solution (33.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 22 mM KH<sub>2</sub>PO<sub>4</sub>, 8.55 mM NaCl, 9.35 mM NH<sub>4</sub>Cl) supplemented  
343 with 20 μM uracil, 60 μM threonine, 60 μM leucine, 20 μM histidine, 22 μM glucose, 2 mM  
344 MgSO<sub>4</sub>, and 100 μM CaCl<sub>2</sub>. OD<sub>600</sub> was determined every 30 min for 8 h and again 24 h after  
345 the start of the experiment. Samples corresponding to ~ 20 mg *E. coli* wet weight were taken at  
346 OD<sub>600</sub> 0.2 (50 ml), 0.4 (15 ml), 0.7 (10 ml) and at time point 24 h (4 ml) and centrifuged  
347 (2000 x g) at 4°C for 10 min. Of the resulting supernatant 250 μl were directly added to an  
348 Eppendorf tube containing 750 μl ice-cold MeOH. Tubes were incubated 20 min at -20°C,  
349 centrifuged (14,000 rpm) for 10 min at 4°C and 400 μl of supernatant were transferred to LC-  
350 MS glass vials, dried down in a speed vacuum concentrator and stored at -20°C until analysis.  
351 Samples were dissolved in 20 μl 50:50 MeOH:H<sub>2</sub>O of which 2 μl were injected into the  
352 Agilent 1290 LC-system connected to a 6550 Agilent Q-TOF mass spectrometer and an  
353 electrospray ionization (ESI) source was used. Data was collected in negative ionization mode.  
354 ESI (Agilent Jetstream) settings were as follows; gas temperature 300°C, gas flow 8 l/min,  
355 nebulizer pressure 40 psi, sheet gas temperature 350°C, sheet gas flow 11, Vcap 4000,  
356 fragmentor 100, Skimmer1 45 and OctapoleRFPeak 750. Medium metabolites were separated  
357 using reverse phase chromatography (Kinetex C18, 100 mm \* 2.1 mm, 2.6 μM 100 Å,  
358 Phenomenex). For reversed phase elution, solvents were prepared as follows (A) H<sub>2</sub>O, 0.1 %  
359 formic acid (B) 75:25 acetonitrile: isopropanol, 0.1% formic acid. All solvents were of HPLC  
360 grade. Linear gradients were devised as follows for reversed phase separation (0.5 ml/minute)  
361 minute 0: 5%B, minute 8: 95%B, minute 10: 95%B, minute 10.2: 5%B, minute 12: 5%B. Data  
362 was analyzed using Mass Hunter Qual (Agilent) using the “find by formula” function with a  
363 match tolerance for masses of 10 ppm and for retention times of 0.35 min. Metabolites were  
364 identified using synthetic standards.

365

## 366 **2.8 Data analyses**

367 All data were analyzed as indicated and visualized using GraphPad Prism version 8 for  
368 Windows (GraphPad Software, San Diego California USA, [www.graphpad.com](http://www.graphpad.com)).

369


## 370 **3. Results**

### 371 **3.1 Production of 3HDec in media of *E. coli* stationary growth phase**

372 It is still under debate whether MCFAs are the endogenous agonists of GPR84, since so far their  
373 presence in relevant tissues at appropriate concentrations remains to be demonstrated [19].  
374 However, 3-hydroxy MCFAs, including 3-hydroxydecanoic acid (3HDec), which has  
375 previously been shown to exert agonistic activity at both HCA<sub>3</sub> and GPR84, are components of  
376 lipopolysaccharides (LPS) in Gram-negative bacteria and used as endotoxin markers in clinical  
377 samples [10]. An *in vitro* approach was chosen to determine, whether 3-hydroxy MCFAs are  
378 present in the growth media of Gram-negative bacteria. We sampled media from different  
379 phases of the growth curve of the gram-negative *E. coli* K-12 MG1655 strain (Figure 1A). The  
380 relative concentration of the 3-hydroxy MCFAs, 3HDec, 3-hydroxylauric acid (3HLau) and  
381 3-hydroxymyristic acid (3HMyr) was measured and found to be increased over time, with the  
382 highest levels in the stationary phase of the *E. coli* cultures (Figure 1B).

383





**Figure 1: 3-hydroxy medium chain fatty acid concentration is increased in *E. coli* growth medium. HCA<sub>3</sub> and GPR84 are functionally expressed in THP-1-M1 macrophages.**

(A) OD<sub>600</sub> of *E. coli* K-12 MG1655, cultured in M9 mineral medium was determined (mean ± SEM, n = 2 experiments, each 5 replicates). At the time points highlighted in grey, samples corresponding to ~20 mg *E. coli* wet weight were taken and centrifuged. (B) 250 μl of the resulting supernatant medium were extracted and analyzed using LC-MS. Shown are the relative concentrations, i.e. area counts under the curves (each as x-fold of values obtained for sample OD<sub>600</sub> = 0.2) shown as min to max with line at mean for 3-hydroxydecanoic acid (3HDec), 3-hydroxylauric acid (3HLau) and 3-hydroxymyristic acid (3HMyr). (C) The mRNA expression of HCA<sub>3</sub> and GPR84 in THP-1 cells differentiated to M0-, M1- or M2-like macrophages (n = 3, reference gene ACTB C<sub>q</sub> = 16) is shown as ΔC<sub>q</sub>-values (mean ± SEM). (D) cAMP inhibitory signaling induced by HCA<sub>3</sub> and GPR84 agonists was examined in THP-1-M1 macrophages in absence (w/o = 2.5 ± 0.3 nM cAMP/well is set 100%) and presence of PTX (w/o = 8.0 ± 1.5 nM cAMP/well is set 100%) and shown as mean ± SEM, n = 3). (E) Agonist-induced phosphorylation of endogenous ERK 1/2 and AKT1/2/3 in cellular lysates of THP-1-M1 macrophages stimulated with HCA<sub>3</sub> and GPR84 agonists mean ± SEM (n ≥ 3). (F) Fura 2-based Ca<sup>2+</sup> imaging experiments were performed in non-transfected THP-1-M1 macrophages. The fluorescence ratio (F340/F380) represents the time course of the intracellular Ca<sup>2+</sup> concentration. Each trace represents the average Ca<sup>2+</sup> signal ± SEM of 31-35 cells derived from single experiments. (G) Intracellular IP<sub>1</sub> levels in response to HCA<sub>3</sub> and GPR84 agonists as mean ± SEM (n = 5). (B, E, G) Statistical analyses were performed applying paired two-tailed t-tests. \* P ≤ 0.05; \*\* P ≤ 0.01; \*\*\* P ≤ 0.001.

### 3.2 HCA<sub>3</sub> and GPR84 are highly expressed and functionally active in THP-1-derived inflammatory macrophages

As previously shown, 3HDec activates the Gα<sub>i</sub>-coupled receptors, HCA<sub>3</sub> and GPR84 [5], which are often co-expressed in innate immune cells, namely monocytes, macrophages and neutrophils (PMNs). Here, we established differentiated and polarized THP-1 cells as a macrophage model to study HCA<sub>3</sub> and GPR84. Highest mRNA expression of both, HCA<sub>3</sub> and GPR84, was found in THP-1 cells polarized to M1-like macrophages (referred to as THP-1-M1) (Figure 1C). We performed cyclic AMP (cAMP) inhibition assays in absence and presence of


413 the  $G\alpha_{i/o}$ -protein inhibitor pertussis toxin (PTX). All tested GPR84 agonists (C10,  
414 6-n-octylaminouracil (6-OAU)) and HCA<sub>3</sub> agonists (3HO, D-PLA, IPBT-5CA) as well as the  
415 common agonist 3HDec induced a PTX-sensitive reduction of intracellular cAMP levels  
416 (Figure 1D). Previously, we demonstrated ERK activation in non-immune cells with  
417 heterologously expressed HCA<sub>3</sub> or GPR84 [5]. However, in THP-1-M1 macrophages, only  
418 GPR84-activating agonists (C10, 3HDec, 6-OAU) but not the HCA<sub>3</sub>-specific agonists (3HO,  
419 D-PLA, IPBT-5CA) increased pERK/total ERK and pAKT/total AKT ratios (Figure 1E).  
420 Further, Ca<sup>2+</sup> imaging experiments in single THP-1-M1 cells were performed to investigate the  
421 involved signaling components. The compounds, N-formylmethionyl-leucyl-phenylalanine  
422 (fMLP) and ATP, used to verify general responsiveness of the cells, evoked moderate or strong  
423 Ca<sup>2+</sup> responses (Figure 1F). The GPR84 agonist C10, the most potent GPR84 agonist 6-OAU,  
424 and the shared agonist 3HDec induced moderate and graded Ca<sup>2+</sup> elevations while the HCA<sub>3</sub>  
425 agonists (3HO, IPBT-5CA) failed to evoke Ca<sup>2+</sup> signals (Figure 1F). Ca<sup>2+</sup> mobilization can be  
426 induced by inositol phosphate, which is produced upon activation of  $G\alpha_{q/11}$  protein-coupled  
427 receptors. Hematopoietic cells specifically express the  $G\alpha_{15}$  protein (GNA15), which belongs  
428 to the  $G\alpha_{q/11}$  protein family. Thus, inositol monophosphate (IP<sub>1</sub>) accumulation as a measure for  
429 phospholipase C (PLC) activity downstream of  $G\alpha_{q/11}/G\alpha_{15}$  signaling was measured [20,21].  
430 Again, only C10, 6-OAU and 3HDec induced a significant increase in IP<sub>1</sub> levels (Figure 1G).

### 431 432 ***3.3 GPR84 couples to the $G\alpha_{15}$ protein, causing ERK activation, IP<sub>1</sub> accumulation and Ca<sup>2+</sup>*** 433 ***signaling in inflammatory macrophages***

434 To determine receptor-specificity of the activated signaling components, we transfected  
435 THP-1-M1 macrophages with siRNA targeting HCA<sub>3</sub>, GPR84 or  $G\alpha_{15}$  mRNA (siGNA15).  
436 Successful knockdown was confirmed using RT-qPCR although only about 40 % reduction of  
437 GPR84 mRNA expression could be achieved as compared to 60 % for HCA<sub>3</sub> and 70 % for  $G\alpha_{15}$   
438 (Figure 2A). No specific high quality antibody targeting GPR84 or HCA<sub>3</sub> are available. To test  
439 whether reduced GPR84 and HCA<sub>3</sub> mRNA levels translate to decreased protein expression, we  
440 used HEK293-T cells, which do not express either receptor endogenously. We co-transfected  
441 HEK293-T cells with plasmids encoding HA-tagged HCA<sub>3</sub> or HA-tagged GPR84 in  
442 combination with receptor-specific siRNA or siNC. Cell surface expression of the HA-tagged  
443 HCA<sub>3</sub> protein was about 60 % decreased in presence of siHCA<sub>3</sub> as compared to siNC, while  
444 cell surface expression of HA-tagged GPR84 protein was about 40 % decreased in presence of  
445 siGPR84 as compared to siNC (Figure S1). Using cAMP inhibition assays, both HCA<sub>3</sub> agonists  
446 (3HO, D-PLA) caused a reduction of intracellular cAMP levels that was abolished by siRNA-  
447 mediated knockdown of HCA<sub>3</sub> (siHCA<sub>3</sub>) (Figure 2B). Despite limited efficacy, siRNA-  
448 mediated knockdown of GPR84 significantly inhibited the C10- and 6-OAU-induced reduction  
449 of intracellular cAMP levels while knockdown of HCA<sub>3</sub> had no effect (Figure 2B). The 3HDec-  
450 mediated decrease in cAMP levels was partially inhibited by siHCA<sub>3</sub> or siGPR84, respectively  
451 (Figure 2B). Next, we tested the PTX sensitivity as well as involvement of GPR84, HCA<sub>3</sub> and  
452  $G\alpha_{15}$  in ERK and AKT phosphorylation. ERK phosphorylation induced by GPR84 agonists was  
453 reduced in presence of PTX and abolished when cells were transfected with siGPR84 or  
454 siGNA15 (Figure 2C). Pre-incubation with PTX caused a complete loss, while siGPR84 but  
455 not siGNA15 caused a reduction of GPR84 agonist-mediated AKT activation (Figure 2D).  
456 Thus, although knockdown efficiency of GPR84 did not exceed 40 %, the significant loss of  
457 signaling upon activation by the GPR84-specific surrogate agonist 6-OAU (Figures 2C, 2D)  
458 supports that the GPR84 level is sufficiently reduced by the siRNA used. To test the  
459 involvement of  $G\alpha_{15}$  in Ca<sup>2+</sup> signaling, the GPR84-specific surrogate agonist 6-OAU, which  
460 induces maximal Ca<sup>2+</sup> responses, was used for measurements in non-transfected, siNC-  
461 transfected (negative control siRNA) and siGNA15-transfected THP-1-M1 macrophages.

462 Knockdown of  $G\alpha_{15}$  inhibited the 6-OAU-induced  $Ca^{2+}$  responses whereas siNC had no effect  
 463 (Figure 2E).

464 In summary, GPR84, a receptor known to couple exclusively to  $G\alpha_{i/o}$  proteins [22], but not  
 465 HCA<sub>3</sub>, transduces its signals in THP-1-M1 macrophages also via the  $G\alpha_{15}$  protein, a hitherto  
 466 unknown characteristic.




467 **Figure 2: Activation of GPR84 causes  $G\alpha_{15}$ -mediated ERK activation and  $Ca^{2+}$  signaling in THP-1-M1**  
 468 **macrophages.**

469 (A) THP-1-M1 macrophages were transfected with either siHCA<sub>3</sub>, siGPR84, siGNA15 (targeting  $G\alpha_{15}$ -mRNA) or  
 470 siNC (negative Ctrl siRNA), which caused ~ 60 %, ~ 40 % and ~ 70 % reduction in respective mRNA levels as  
 471 detected using RT-qPCR. (B) cAMP inhibitory signaling induced by HCA<sub>3</sub> and GPR84 agonists was examined in  
 472 THP-1-M1 macrophages after transfection with siHCA<sub>3</sub>, siGPR84 or siNC. Agonist-induced phosphorylation of  
 473 endogenous ERK 1/2 (C) and AKT1/2/3 (D) were measured in cellular lysates of THP-1-M1 macrophages in  
 474 absence and presence of PTX or macrophages transfected with siNC, siHCA<sub>3</sub>, siGPR84 and siGNA15, w/o was  
 475 set 1, respectively. (E) 1  $\mu$ M of the GPR84-specific surrogate agonist 6-OAU induced a similar  $Ca^{2+}$  signal in non-  
 476 transfected and siNC-transfected cells, which was diminished in siGNA15-transfected cells, while the ATP-  
 477 induced  $Ca^{2+}$  response was not visibly affected. The change ( $\Delta$ ) in the fluorescence ratio (F340/F380) for the 6-  
 478 OAU-induced  $Ca^{2+}$  signals in non-transfected (nt), siNC- and siGNA15-transfected cells is depicted as mean  
 479  $\pm$  SEM from n = 4 experiments per group (each experiment containing 37 - 47 cells). Data is shown as (A, B)  
 480 mean  $\pm$  SEM (C, D) min to max with line at mean (n = 3 to 6 independent experiments). Statistical analyses were  
 481 performed applying unpaired t-tests. \* P  $\leq$  0.05; \*\* P  $\leq$  0.01; \*\*\* P  $\leq$  0.001.

482  
 483  
 484 **3.4 GPR84 triggers tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) secretion, activation of nuclear**  
 485 **factor  $\kappa$  B (NF $\kappa$ B) and NADPH oxidase-dependent ROS production in inflammatory**  
 486 **macrophages**

487 It was previously shown in mouse M1 macrophages that GPR84 activation by 6-OAU results  
 488 in activation of NF $\kappa$ B and increases TNF $\alpha$  levels [6]. We confirmed this effect in human  
 489 THP-1-M1 macrophages and found that stimulation with C10, 3HDec and 6-OAU increased  
 490 the release of TNF $\alpha$ , whereas only C10 and 6-OAU, but not 3HDec activated NF $\kappa$ B (Figures  
 491 S2A, S2B).




**Figure 3: GPR84 agonists stimulate NADPH oxidase-dependent ROS production in inflammatory macrophages.**

(A) Production of reactive oxygen species (ROS) in THP-1-M1 macrophages was examined by adding DHR123 (dihydrorhodamine 123) to the cells and assessing differences in the intracellular DHR123 fluorescence intensity after incubation with GPR84 agonists in the absence and presence of the NADPH-oxidase (NOX) inhibitor diphenyleneiodonium chloride (DPI, 4  $\mu$ M). PMA was used as a positive control. Representative images and analyses performed using the Celigo Imaging Cytometer are shown. The sum of green pixel intensities in all segmented cells per well, correlating to DHR123 integrated intensity in the absence (measure for overall ROS-production) and presence of DPI (measure for NOX-independent ROS-production) was used to determine total ROS and NOX-dependent ROS-production (n = 7). (B) THP-1-M1 macrophages were transfected with either siHCA<sub>3</sub>, siGPR84, siGNA15 or siNC. ROS and NOX-dependent ROS was determined (n = 5) (A, B) Green pixel intensities in absence of agonist were set 100 %. Normalized total ROS and NOX-dependent ROS is shown as floating bars min to max, line at mean. Statistical analyses were performed applying an unpaired t-test. \* P  $\leq$  0.05; \*\* P  $\leq$  0.01; \*\*\* P  $\leq$  0.001.

Both, TNF $\alpha$  and NF $\kappa$ B signaling are known to be associated with the production of reactive oxygen species (ROS) [23,24]. The enzyme NADPH oxidase (NOX) is crucial for ROS production in immune cells as part of the defense mechanism against invading pathogens [25]. We measured intracellular ROS production in THP-1-M1 macrophages using dihydrorhodamine 123 (DHR123). In cells stimulated with GPR84 agonists for 24 h, the DHR123 intensity was lower in the presence of the NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI), indicating NOX-dependent production of ROS (Figures 3A). To test for differences in the overall intracellular ROS production, we analyzed DHR123 intensity in the absence of DPI. 3HDec and C10 increased total and NOX-mediated ROS formation in THP-1-M1 macrophages, as did the positive control compound phorbol 12-myristate 13-acetate (PMA), but not 6-OAU (Figures 3A, S2C). To determine, whether the 3HDec- and C10-induced increase in total and NOX-dependent ROS was evoked by GPR84 and G $\alpha_{15}$ , siRNA-mediated knockdown experiments were performed (Figure 3B). These analyses revealed, despite knockdown efficiency of only 40 %, that solely GPR84 caused the increase in ROS upon stimulation with 3HDec and C10 (Figure 3B). Furthermore, the ROS production in presence of 3HDec and C10 was significantly reduced in macrophages transfected with siGNA15, but was still increased compared to the control, suggesting that G $\alpha_{15}$  is mainly but not exclusively responsible for this effect (Figure 3B).





526  
 527 **Figure 4: HCA<sub>3</sub> agonists decrease ROS production and IL-1β secretion but increase IL-10 secretion and**  
 528 **enhance cellular respiration in THP-1-M1 macrophages.**  
 529 (A) Production of reactive oxygen species (ROS) in THP-1-M1 macrophages after incubation with HCA<sub>3</sub> agonists  
 530 in the absence and presence of the NADPH-oxidase (NOX) inhibitor diphenyleneiodonium chloride (DPI, 4 μM)  
 531 (mean ± SEM of n = 7). Normalized total ROS and NOX-dependent ROS is shown as min to max, line at mean.  
 532 (B) IL-1β and IL-10 concentrations (in pg/ml, min to max, line at mean of n ≥ 4 biological replicates) in cell culture  
 533 supernatants of THP-1-M1 macrophages stimulated with HCA<sub>3</sub> agonists. (C) The components of the electron  
 534 transport chain are localized in mitochondria and the oxygen consumption rate (OCR) and extracellular  
 535 acidification rate (ECAR) were analyzed in THP-1-M1 macrophages (created using BioRender.com). (D) Shown  
 536 are metabolic parameters calculated from the OCR and ECAR measurements as described in Material and  
 537 Methods. Data depicted as floating bars min to max, line at mean of 3 time points of 4 independent experiments  
 538 (n = 12), each carried out in 4 technical replicates. Statistical analyses (w/o versus agonists) were performed using  
 539 a repeated measures One-Way ANOVA \* P ≤ 0.05; \*\* P ≤ 0.01; \*\*\* P ≤ 0.001.

540  
 541 **3.5 HCA<sub>3</sub> triggers anti-inflammatory signaling via reduction of ROS production and IL-1β**  
 542 **secretion but increase of IL-10 secretion and cellular respiration in inflammatory macrophages**

543 In contrast to GPR84 agonists, HCA<sub>3</sub> activation had no effect on NFκB activation or TNFα  
 544 secretion (Figures S2A, S2B), but caused a significant decrease in total and NOX-dependent  
 545 ROS levels, suggesting an anti-inflammatory action (Figure 4A). In contrast to GPR84, little is  
 546 known about HCA<sub>3</sub>-mediated immune cell functions. To further elucidate the potential anti-  
 547 inflammatory role of HCA<sub>3</sub>, we analyzed the effect of HCA<sub>3</sub> agonists on the secretion of IL-  
 548 10, an anti-inflammatory cytokine and IL-1β, a pro-inflammatory cytokine in THP-1-M1  
 549 macrophages. IL-1β concentrations in the supernatant were significantly reduced, when cells  
 550 were stimulated with the HCA<sub>3</sub> agonists 3HO, D-PLA or IPBT-5CA (surrogate HCA<sub>3</sub>-specific  
 551 agonist), while IL-10 release was significantly increased (Figure 4B). Cellular metabolism and  
 552 macrophage function are tightly linked and IL-10 has been shown to inhibit inflammation-  
 553 induced glycolysis while promoting oxidative phosphorylation in macrophages [16,26]. We  
 554 performed metabolic flux analyses using the Seahorse Mito Stress Test (Agilent). Oxygen  
 555 consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in

556 THP-1-M1 macrophages stimulated with HCA<sub>3</sub> agonists in the absence and presence of  
557 selective inhibitors of the electron transport chain (ETC) (Figure 4C). HCA<sub>3</sub> agonists caused an  
558 increase in basal respiration, associated with an increased proton leakage, but not ATP  
559 production (Figures 4D, S3). This is accompanied by a decreased basal ECAR indicating a  
560 lower glycolytic rate. This resulted in a significantly increased ratio of basal respiration/ECAR  
561 but reduced spare respiratory capacity (Figures 4D, S3). HCA<sub>3</sub> agonists affected neither  
562 maximal respiration nor non-mitochondrial oxygen consumption (Figure S3).  
563 In summary, this indicates that HCA<sub>3</sub> activation enhances aerobic respiration (oxidative  
564 phosphorylation), while the rate of glycolysis is reduced. This is a characteristic metabolic  
565 feature associated with anti-inflammatory responses of macrophages [16]. Macrophages are  
566 mostly tissue-resident descendants of circulating monocytes. The most abundant circulating  
567 leukocytes in humans and the first responders to an infection are neutrophils [27]. Thus, we  
568 analyzed the role of HCA<sub>3</sub> and GPR84 for neutrophil function.

569

### 570 **3.6 HCA<sub>3</sub> stimulation counteracts GPR84-induced PMN activation**


571 In PMNs, high mRNA expression of both receptors and functional presence using dynamic  
572 mass redistribution (DMR) measurements was verified (Figures 5A, 5B). DMR is a label-free  
573 technique and therefore highly suitable for signaling analysis in primary cells to determine time-  
574 resolved receptor activation independent of second messenger levels. Stimulation of PMNs  
575 with all HCA<sub>3</sub> agonists resulted in DMR responses completely suppressed by PTX, indicating  
576 coupling to Gα<sub>i/o</sub>-proteins (Figure 5B). Both, 3HDec and C10, induced a partially PTX-  
577 insensitive DMR response, suggesting involvement of additional signaling pathways apart from  
578 Gα<sub>i/o</sub> stimulation (Figure 5B). Furthermore, GPR84 agonists activated ERK but not AKT in  
579 PMNs (Figure S4A).

580 PMNs are the most abundant circulating leukocytes in humans and able to form neutrophil  
581 extracellular traps (NET) [28]. Released DNA, reflecting NET formation, can be stained with  
582 propidium iodide (PI) [29]. Here, the ratio of cell counts positive for PI and for Hoechst 33342  
583 (total cell number) derived from image-based analyses were used to quantify activation of  
584 PMNs (Figures 5C, S4B). C10 and 3HDec induced a significant increase in activated PMNs  
585 (Figure 5C). PMA served as positive control and resulted in almost 100 % activation, reflected  
586 by a ratio of PI count/Hoechst 33342 count of ~1 (Figure 5C). Some GPCRs in immune cells  
587 amplify or counteract signals induced by other receptors. We found that presence of the HCA<sub>3</sub>-  
588 specific agonists D-PLA and IPBT-5CA caused a significant reduction of the 3HDec- or C10-  
589 induced PMN activation (Figure 5C).

590 NET formation can be lytic, leading to cell death (suicidal NETosis) or resulting in the  
591 formation of functional anuclear cytoplasts capable of phagocytosis (vital NETosis) [30,31].  
592 We analyzed the effect of HCA<sub>3</sub> or GPR84 stimulation on phagocytic activity of PMNs by  
593 treatment with HCA<sub>3</sub> agonists, GPR84 agonists or PMA (positive control) and subsequent  
594 addition of pHrodo Red-conjugated *E. coli* particles (Figure 5D). These particles show  
595 pH-sensitive fluorescence upon ingestion into acidic phagosomes. The actin cytoskeleton was  
596 stained using Alexa Fluor 488-labeled phalloidin while the nuclei were stained with Hoechst  
597 33342 (Figure 5D). Automatic image-based analyses were performed to determine: (1) the  
598 number of cell bodies (green), containing (blue) or lacking an intact nucleus, (2) the number of  
599 phagocytic cells (green and red), and (3) the average number of particles per cell (red per green  
600 cell body) (Figure 5D).

601 Upon stimulation with C10, 3HDec or the positive control PMA a reduced number of cells were  
602 containing nuclei consequently leading to an increased number of cells lacking nuclei (Figure  
603 5D). Additionally, the same treatments lead to a significantly decreased number of phagocytic  
604 cells, i.e. of cell bodies containing *E. coli* particles (Figure 5D). At last, the number of particles  
605 ingested per phagocytic cell was determined. Although we detected a lower number of

606 phagocytic cells when PMNs were stimulated with 3HDec or C10, we found a significantly  
 607 higher number of ingested particles per cell body under these conditions (Figure 5D).  
 608 C10 and 3HDec induce both suicidal NETosis (Figure 5C) and vital NETosis, supported by the  
 609 increased phagocytic capacity (Figures 5D).  
 610



611  
 612 **Figure 5: C10 and 3HDec induce activation of primary human neutrophils, counteracted by HCA<sub>3</sub> agonists.**  
 613 (A) The mRNA expression of HCA<sub>3</sub> and GPR84 in freshly isolated human PMNs (n = 4 different donors, reference  
 614 genes ACTB C<sub>q</sub> = 16 and B2M C<sub>q</sub> = 17) is shown as ΔC<sub>q</sub>-values (mean ± SEM, each sample measured in  
 615 duplicates). (B) Dynamic mass redistribution (DMR) responses in PMNs (mean ± SEM of n = 4 different donors)  
 616 upon stimulation with HCA<sub>3</sub> and GPR84 agonists with or without PTX preincubation. (C) PMNs were incubated  
 617 with HCA<sub>3</sub>, GPR84 agonists or PMA, stained with propidium iodide (PI, red) and Hoechst 33342 (blue). The  
 618 number of activated (PI) / total cells (Hoechst 33342) was determined. (D) PMN nuclei were stained with Hoechst  
 619 33342, cytoskeleton was stained using AlexaFluor488-phalloidin (F-Actin) and phagocytosis of pHrodo Red-  
 620 conjugated *E. coli* particles was assessed. Data is shown as percent of numbers determined in absence of agonists.  
 621 (C) n ≥ 10 and (D) n = 5 independent experiments each performed with PMNs of different donors, carried out in  
 622 triplicates, is shown as min to max, line at mean. Statistical analyses were performed applying paired two-tailed t-  
 623 test. \* P ≤ 0.05; \*\* P ≤ 0.01; \*\*\* P ≤ 0.001. Cell illustrations in D were created with BioRender.com.  
 624

## 625 4. Discussion


626 GPR84 and HCA<sub>3</sub> are known to couple to G $\alpha_{i/o}$  proteins and exhibit overlapping expression in  
627 monocytes, macrophages and neutrophils (reviewed in [19]). While GPR84 is a widely studied  
628 receptor, constituting an attractive pharmacological target for the development of anti-  
629 inflammatory drugs, data on HCA<sub>3</sub> function in immune cells is rather scarce. Several surrogate  
630 GPR84 ligands have been discovered but little is known about the signaling components  
631 involved in the pro-inflammatory effects induced upon GPR84 activation (reviewed in [19]).  
632 For HCA<sub>3</sub> on the other hand, a receptor only present in humans and great apes, anti-  
633 inflammatory action has been suggested, but more detailed insights are lacking [5]. The  
634 3-hydroxy MCFA 3HDec, a gram-negative bacterial-derived MCFA, activates both GPR84 and  
635 HCA<sub>3</sub>, which exhibit opposing effects in innate immune cells. Therefore, deciphering GPR84-  
636 and HCA<sub>3</sub>-activated signaling pathways and their physiological consequences helps to further  
637 define their therapeutic potential.

638 Here, we unraveled the molecular differences in GPR84- and HCA<sub>3</sub>-mediated signaling in  
639 innate immune cells. We conducted functional analyses to determine consequences for immune  
640 cell responses upon activation of those two GPCRs. Regarding the origin of 3HDec, we showed  
641 that levels of 3-hydroxy MCFAs strongly accumulate in association with the increasing death  
642 of gram-negative bacteria, like *E. coli* (Figure 1B). Previous studies had also shown in other  
643 contexts that 3HDec and 3-hydroxy derivatives of other MCFAs are degradation products of  
644 LPS [32,33]. In a heterologous expression system we showed recently that signaling kinetics  
645 and components involved in signal transduction of GPR84 and HCA<sub>3</sub> differ upon activation by  
646 3HDec [5]. However, here we found that in human macrophages and primary human  
647 neutrophils, the HCA<sub>3</sub>-dependent signaling upon 3HDec stimulation is negligible, while 3HDec  
648 as well as C10 mediate pro-inflammatory signaling through activation of G $\alpha_{15}$ -coupled GPR84  
649 (Figures 2B-2E, 3B). To our best knowledge, coupling of GPR84 to G $\alpha_{15}$  in addition to G $\alpha_{i/o}$   
650 has not been described before. In a physiological context, one may speculate that elimination  
651 of bacteria by innate immune cells is accompanied by a release of LPS-derived 3-hydroxy  
652 MCFAs, causing local concentrations high enough to activate GPR84 followed by recruitment  
653 and activation of further immune cells. Thus, it is conceivable that LPS-derived 3-hydroxy  
654 MCFAs are the physiological relevant GPR84 agonists. Future analytical studies examining  
655 local concentrations of 3-hydroxy MCFAs in infected / inflamed tissue may shed further light  
656 on this aspect. It has previously been shown that G $\alpha_{15}$  couples chemoattractant receptors  
657 efficiently to PLC $\beta$  and NF $\kappa$ B activation [34]. This is in line with our observations of GPR84-  
658 mediated increase of intracellular Ca<sup>2+</sup>, IP<sub>3</sub> and NF $\kappa$ B activation (Figures 1F, 1G, 2E, S2B).  
659 Further, we provide evidence for GPR84-, G $\alpha_{15}$ -dependent ERK activation and ROS production  
660 in macrophages (Figures 2C, 3B, 6). In neutrophils, which are the most abundant circulating  
661 leukocytes in humans and the first responders to an infection [27], GPR84 activation with C10  
662 or 3HDec resulted in activation of neutrophils (suicidal NETosis), which is the defining step in  
663 the inflammatory response (Figure 5C). At the same time phagocytic capacity (vital NETosis)  
664 was increased, further highlighting a role of GPR84 in pro-inflammation (Figures 5D, 6).  
665 Several studies already highlighted GPR84 as chemoattractant receptor [6,8,35]. Assuming that  
666 neutrophils and macrophages are recruited to the side of bacterial infection due to locally  
667 increasing 3HDec levels, GPR84 activation will then lead to G $\alpha_{15}$ -dependent NETosis,  
668 phagocytosis and ROS production to limit the infection.

669 HCA<sub>3</sub> signaling, on the contrary, did not affect neutrophil activation/phagocytosis by itself but  
670 counteracted GPR84-mediated PMN activation, potentially to prevent damage resulting from  
671 excess activation of PMNs (Figures 5C, 6). Thus, HCA<sub>3</sub> may be especially important for  
672 balancing the response of innate immune cells at the site of a bacterial infection. HCA<sub>3</sub> tones  
673 down pro-inflammatory IL-1 $\beta$  secretion and ROS production, but increases anti-inflammatory  
674 IL-10 secretion from macrophages (Figures 4A, 4B, 6). This is a potential mechanism to prevent



675 excessive damage of surrounding tissue and/or to help resolve the inflammation by reducing  
 676 the recruitment of further immune cells through lowering cytokine release [36]. Cellular  
 677 metabolism is tightly linked to macrophage function and the activity of various metabolic  
 678 pathways is linked to pro- or anti-inflammatory signaling [37]. From an immunometabolic  
 679 point, HCA<sub>3</sub> activation caused a decrease in glycolytic activity but increase in oxidative  
 680 phosphorylation (Figures 4D). This kind of metabolic phenotype is rather associated with anti-  
 681 inflammatory responses, while pro-inflammation is usually accompanied by strong dependence  
 682 on glycolysis (reviewed in [16]). LAB-derived metabolites, like e.g. D-PLA activating HCA<sub>3</sub>,  
 683 are also known to exhibit anti-bacterial and anti-fungal properties rendering the presence of  
 684 pathogenic microbes in LAB-fermented food, like Sauerkraut, less likely [38,39]. In this  
 685 scenario, it appears reasonable to speculate that HCA<sub>3</sub> activated by D-PLA induces a  
 686 hyporesponsiveness in neutrophils and macrophages, preventing excessive cytokine release and  
 687 therefore inflammation.  
 688



689  
 690 **Figure 6: GPR84 and HCA<sub>3</sub> regulate innate immune cell functions.**  
 691 THP-1-M1 macrophages and primary human neutrophils express both, GPR84 and HCA<sub>3</sub>. HCA<sub>3</sub> is exclusively  
 692 coupled to Gα<sub>i/o</sub>. Activation of HCA<sub>3</sub> results in decreased IL-1β but increased IL-10 secretion. Less ROS are  
 693 produced and macrophage metabolism shifts to a less glycolytic phenotype in presence of HCA<sub>3</sub> agonists. GPR84  
 694 is coupled to Gα<sub>i/o</sub> and Gα<sub>15</sub> in THP-1-M1 macrophages. Activation of GPR84 causes Gα<sub>15</sub>-dependent ERK  
 695 activation and increases intracellular Ca<sup>2+</sup> and IP<sub>3</sub> levels. NFκB activation, TNFα secretion and formation of ROS  
 696 are increased upon stimulation of GPR84. GPR84 agonists cause neutrophil activation and enhanced phagocytosis,  
 697 which is inhibited in presence of HCA<sub>3</sub> agonists (created with BioRender.com).  
 698

## 699 5. Conclusions

700 In conclusion, we provide new insights into the molecular regulation of innate immune cells by  
 701 HCA<sub>3</sub> and GPR84 (Figure 6). We propose that both receptors can serve as new targets to tackle  
 702 chronic inflammation. Our discovery of Gα<sub>15</sub> as a crucial mediator of GPR84-induced pro-  
 703 inflammatory signaling provides a key step towards a better assessment of the potential of  
 704 GPR84 as drug target. Future studies shall focus on this aspect to determine potency and  
 705 efficacy of GPR84-targeting ligands.

## 706 6. Acknowledgements

707 This work was supported by the German Research Foundation (Project number 407707190),  
 708 by the European Social Funds and research funding of the Medical Faculty, University Leipzig.  
 709 We thank Torsten Schöneberg for critical reading and commenting on the manuscript.  
 710

711 **7. References**

- 712 [1] J. Wang, X. Wu, N. Simonavicius, H. Tian, L. Ling, Medium-chain fatty acids as ligands  
713 for orphan G protein-coupled receptor GPR84, *J. Biol. Chem.* 281 (2006) 34457–34464.  
714 <https://doi.org/10.1074/jbc.M608019200>.
- 715 [2] K. Ahmed, S. Tunaru, C.-D. Langhans, J. Hanson, C.W. Michalski, S. Kölker, P.M.  
716 Jones, J.G. Okun, S. Offermanns, Deorphanization of GPR109B as a receptor for the  
717 beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis,  
718 *J. Biol. Chem.* 284 (2009) 21928–21933. <https://doi.org/10.1074/jbc.M109.019455>.
- 719 [3] A. Peters, P. Krumbholz, E. Jäger, A. Heintz-Buschart, M.V. Çakir, S. Rothmund, A.  
720 Gaudl, U. Ceglarek, T. Schöneberg, C. Stäubert, Metabolites of lactic acid bacteria  
721 present in fermented foods are highly potent agonists of human hydroxycarboxylic acid  
722 receptor 3, *PLoS Genet.* 15 (2019) e1008145.  
723 <https://doi.org/10.1371/journal.pgen.1008145>.
- 724 [4] Y. Irukayama-Tomobe, H. Tanaka, T. Yokomizo, T. Hashidate-Yoshida, M.  
725 Yanagisawa, T. Sakurai, Aromatic D-amino acids act as chemoattractant factors for  
726 human leukocytes through a G protein-coupled receptor, GPR109B, *Proc. Natl. Acad.*  
727 *Sci. U. S. A.* 106 (2009) 3930–3934. <https://doi.org/10.1073/pnas.0811844106>.
- 728 [5] A. Peters, P. Rabe, P. Krumbholz, H. Kalwa, R. Kraft, T. Schöneberg, C. Stäubert,  
729 Natural biased signaling of hydroxycarboxylic acid receptor 3 and G protein-coupled  
730 receptor 84, *Cell Commun Signal* 18 (2020) 31. [https://doi.org/10.1186/s12964-020-](https://doi.org/10.1186/s12964-020-0516-2)  
731 [0516-2](https://doi.org/10.1186/s12964-020-0516-2).
- 732 [6] C. Recio, D. Lucy, G.S.D. Purvis, P. Iveson, L. Zeboudj, A.J. Iqbal, D. Lin, C.  
733 O'Callaghan, L. Davison, E. Griesbach, A.J. Russell, G.M. Wynne, L. Dib, C. Monaco,  
734 D.R. Greaves, Activation of the Immune-Metabolic Receptor GPR84 Enhances  
735 Inflammation and Phagocytosis in Macrophages, *Front. Immunol.* 9 (2018) 1419.  
736 <https://doi.org/10.3389/fimmu.2018.01419>.
- 737 [7] M. Suzuki, S. Takaishi, M. Nagasaki, Y. Onozawa, I. Iino, H. Maeda, T. Komai, T. Oda,  
738 Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor, *J.*  
739 *Biol. Chem.* 288 (2013) 10684–10691. <https://doi.org/10.1074/jbc.M112.420042>.
- 740 [8] D. Lucy, G.S.D. Purvis, L. Zeboudj, M. Chatzopoulou, C. Recio, C.J.R. Bataille, G.M.  
741 Wynne, D.R. Greaves, A.J. Russell, A Biased Agonist at Immunometabolic Receptor  
742 GPR84 Causes Distinct Functional Effects in Macrophages, *ACS Chem. Biol.* 14 (2019)  
743 2055–2064. <https://doi.org/10.1021/acscchembio.9b00533>.
- 744 [9] S. Offermanns, S.L. Colletti, T.W. Lovenberg, G. Semple, A. Wise, A.P. IJzerman,  
745 International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and  
746 Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and  
747 GPR109B), *Pharmacol. Rev.* 63 (2011) 269–290. <https://doi.org/10.1124/pr.110.003301>.
- 748 [10] B. Szponar, E. Norin, T. Midtvedt, L. Larsson, Limitations in the use of 3-hydroxy fatty  
749 acid analysis to determine endotoxin in mammalian samples, *Journal of microbiological*  
750 *methods* 50 (2002) 283–289. [https://doi.org/10.1016/s0167-7012\(02\)00038-6](https://doi.org/10.1016/s0167-7012(02)00038-6).
- 751 [11] E. Kolaczowska, P. Kubes, Neutrophil recruitment and function in health and  
752 inflammation, *Nat Rev Immunol* 13 (2013) 159–175. <https://doi.org/10.1038/nri3399>.
- 753 [12] P. Italiani, D. Boraschi, From Monocytes to M1/M2 Macrophages: Phenotypical vs.  
754 Functional Differentiation, *Front. Immunol.* 5 (2014) 514.  
755 <https://doi.org/10.3389/fimmu.2014.00514>.
- 756 [13] D.C. Dale, L. Boxer, W.C. Liles, The phagocytes: neutrophils and monocytes, *Blood* 112  
757 (2008) 935–945. <https://doi.org/10.1182/blood-2007-12-077917>.
- 758 [14] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, *Nat*  
759 *Rev Immunol* 8 (2008) 958–969. <https://doi.org/10.1038/nri2448>.

- 760 [15] E. Mortaz, S.D. Alipoor, I.M. Adcock, S. Mumby, L. Koenderman, Update on  
761 Neutrophil Function in Severe Inflammation, *Front. Immunol.* 9 (2018) 2171.  
762 <https://doi.org/10.3389/fimmu.2018.02171>.
- 763 [16] A. Viola, F. Munari, R. Sánchez-Rodríguez, T. Scolaro, A. Castegna, The Metabolic  
764 Signature of Macrophage Responses, *Front. Immunol.* 10 (2019) 1462.  
765 <https://doi.org/10.3389/fimmu.2019.01462>.
- 766 [17] D.B. Kuhns, D.A.L. Priel, J. Chu, K.A. Zarembek, Isolation and Functional Analysis of  
767 Human Neutrophils, *Curr. Protoc. Immunol.* 111 (2015) 7.23.1-7.23.16.  
768 <https://doi.org/10.1002/0471142735.im0723s111>.
- 769 [18] M. Genin, F. Clement, A. Fattaccioli, M. Raes, C. Michiels, M1 and M2 macrophages  
770 derived from THP-1 cells differentially modulate the response of cancer cells to  
771 etoposide, *BMC Cancer* 15 (2015) 577. <https://doi.org/10.1186/s12885-015-1546-9>.
- 772 [19] V.B. Luscombe, D. Lucy, C.J.R. Bataille, A.J. Russell, D.R. Greaves, 20 Years an  
773 Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?, *DNA and*  
774 *cell biology* 39 (2020) 1926–1937. <https://doi.org/10.1089/dna.2020.5846>.
- 775 [20] N. Mizuno, H. Itoh, Functions and regulatory mechanisms of Gq-signaling pathways,  
776 *Neurosignals.* 17 (2009) 42–54. <https://doi.org/10.1159/000186689>.
- 777 [21] D. Billups, B. Billups, R.A.J. Challiss, S.R. Nahorski, Modulation of Gq-protein-coupled  
778 inositol trisphosphate and Ca<sup>2+</sup> signaling by the membrane potential, *J. Neurosci.* 26  
779 (2006) 9983–9995. <https://doi.org/10.1523/JNEUROSCI.2773-06.2006>.
- 780 [22] S.P. Alexander, J. Battey, H.E. Benson, R.V. Benya, T.I. Bonner, A.P. Davenport, S.  
781 Eguchi, A. Harmar, N. Holliday, R.T. Jensen, S. Karnik, E. Kostenis, W.C. Liew, A.E.  
782 Monaghan, C. Mpamhanga, R. Neubig, A.J. Pawson, J.-P. Pin, J.L. Sharman, M.  
783 Spedding, E. Spindel, L. Stoddart, L. Storzjohann, W.G. Thomas, K. Tirupula, P.  
784 Vanderheyden, Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to  
785 Pharmacology Database, *GtoPdb CITE 2019* (2019).  
786 <https://doi.org/10.2218/gtopdb/F16/2019.5>.
- 787 [23] H. Blaser, C. Dostert, T.W. Mak, D. Brenner, TNF and ROS Crosstalk in Inflammation,  
788 *Trends in cell biology* 26 (2016) 249–261. <https://doi.org/10.1016/j.tcb.2015.12.002>.
- 789 [24] M.J. Morgan, Z. Liu, Crosstalk of reactive oxygen species and NF- $\kappa$ B signaling, *Cell Res*  
790 21 (2011) 103–115. <https://doi.org/10.1038/cr.2010.178>.
- 791 [25] A. Panday, M.K. Sahoo, D. Osorio, S. Batra, NADPH oxidases: an overview from  
792 structure to innate immunity-associated pathologies, *Cell Mol Immunol* 12 (2015) 5–23.  
793 <https://doi.org/10.1038/cmi.2014.89>.
- 794 [26] W.K.E. Ip, N. Hoshi, D.S. Shouval, S. Snapper, R. Medzhitov, Anti-inflammatory effect  
795 of IL-10 mediated by metabolic reprogramming of macrophages, *Science* 356 (2017)  
796 513–519. <https://doi.org/10.1126/science.aal3535>.
- 797 [27] K. Prame Kumar, A.J. Nicholls, C.H.Y. Wong, Partners in crime: neutrophils and  
798 monocytes/macrophages in inflammation and disease, *Cell Tissue Res.* 371 (2018) 551–  
799 565. <https://doi.org/10.1007/s00441-017-2753-2>.
- 800 [28] V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D.S. Weiss, Y.  
801 Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria, *Science* 303  
802 (2004) 1532–1535. <https://doi.org/10.1126/science.1092385>.
- 803 [29] F. Grabcanovic-Musija, A. Obermayer, W. Stoiber, W.-D. Krautgartner, P. Steinbacher,  
804 N. Winterberg, A.C. Bathke, M. Klappacher, M. Studnicka, Neutrophil extracellular trap  
805 (NET) formation characterises stable and exacerbated COPD and correlates with airflow  
806 limitation, *Respir. Res.* 16 (2015) 59. <https://doi.org/10.1186/s12931-015-0221-7>.
- 807 [30] B.G. Yipp, B. Petri, D. Salina, C.N. Jenne, B.N.V. Scott, L.D. Zbyszynski, K. Pittman, M.  
808 Asaduzzaman, K. Wu, H.C. Meijndert, S.E. Malawista, A. de Boissfleury Chevance, K.  
809 Zhang, J. Conly, P. Kuberski, Infection-induced NETosis is a dynamic process involving

- 810 neutrophil multitasking in vivo, *Nat. Med.* 18 (2012) 1386–1393.  
811 <https://doi.org/10.1038/nm.2847>.
- 812 [31] B.G. Yipp, P. Kubes, NETosis: how vital is it?, *Blood* 122 (2013) 2784–2794.  
813 <https://doi.org/10.1182/blood-2013-04-457671>.
- 814 [32] J.-P. Pais de Barros, T. Gautier, W. Sali, C. Adrie, H. Choubley, E. Charron, C. Lalande,  
815 N. Le Guern, V. Deckert, M. Monchi, J.-P. Quenot, L. Lagrost, Quantitative  
816 lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus  
817 ameocyte lysate assay, *J. Lipid Res.* 56 (2015) 1363–1369.  
818 <https://doi.org/10.1194/jlr.D059725>.
- 819 [33] A. Saraf, L. Larsson, H. Burge, D. Milton, Quantification of ergosterol and 3-hydroxy  
820 fatty acids in settled house dust by gas chromatography-mass spectrometry: comparison  
821 with fungal culture and determination of endotoxin by a *Limulus* ameocyte lysate assay,  
822 *Appl. Environ. Microbiol.* 63 (1997) 2554–2559.  
823 <https://doi.org/10.1128/AEM.63.7.2554-2559.1997>.
- 824 [34] M. Yang, H. Sang, A. Rahman, D. Wu, A.B. Malik, R.D. Ye, G alpha 16 couples  
825 chemoattractant receptors to NF-kappa B activation, *J. Immunol.* 166 (2001) 6885–6892.  
826 <https://doi.org/10.4049/jimmunol.166.11.6885>.
- 827 [35] M. Sundqvist, K. Christenson, A. Holdfeldt, M. Gabl, J. Mårtensson, L. Björkman, R.  
828 Dieckmann, C. Dahlgren, H. Forsman, Similarities and differences between the responses  
829 induced in human phagocytes through activation of the medium chain fatty acid receptor  
830 GPR84 and the short chain fatty acid receptor FFA2R, *Biochimica et Biophysica Acta*  
831 (BBA) - Molecular Cell Research 1865 (2018) 695–708.  
832 <https://doi.org/10.1016/j.bbamcr.2018.02.008>.
- 833 [36] G. Schett, M.F. Neurath, Resolution of chronic inflammatory disease: universal and  
834 tissue-specific concepts, *Nat Commun* 9 (2018) 3261. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-018-05800-6)  
835 [018-05800-6](https://doi.org/10.1038/s41467-018-05800-6).
- 836 [37] C. Diskin, E.M. Pålsson-McDermott, Metabolic Modulation in Macrophage Effector  
837 Function, *Front. Immunol.* 9 (2018) 270. <https://doi.org/10.3389/fimmu.2018.00270>.
- 838 [38] L. Li, S.-Y. Shin, K.W. Lee, N.S. Han, Production of natural antimicrobial compound D-  
839 phenyllactic acid using *Leuconostoc mesenteroides* ATCC 8293 whole cells involving  
840 highly active D-lactate dehydrogenase, *Letters in Applied Microbiology* 59 (2014) 404–  
841 411. <https://doi.org/10.1111/lam.12293>.
- 842 [39] N. Rodríguez, J.M. Salgado, S. Cortés, J.M. Domínguez, Antimicrobial activity of d-3-  
843 phenyllactic acid produced by fed-batch process against *Salmonella enterica*, *Food*  
844 *Control* 25 (2012) 274–284. <https://doi.org/10.1016/j.foodcont.2011.10.042>.